Driven by a strong commitment to innovation in Reproductive Medicine, my ambition is to develop lasting solutions and to provide meaningful  information on effectiveness of therapies and prognostic information —ultimately helping couples achieve their goal: an onging pregnancy and healthy child.

My research focuses on advancing the field of assisted reproductive technologies (ART) such as fertility preservation, and recurrent pregnancy loss. I supervised multiple (inter) national clinical trials in women with breastcancer who opt for oocyte freezing, women with recurrent pregnancy loss, and women undergoing embryotransfer (in IVF/ICSI cycles). 

A major part of my work has brought the clinical problem of recurrent miscarriage to the forefront, both nationally and internationally. I introduced selective karyotyping and contributed critical evidence regarding the effectiveness of commonly used treatments such as progesterone, aspirin, heparin, levothyroxine, helping to refine clinical practice. e.g. Progesterone reduces miscarriage rates in women with three earlier miscarriages and bloodloss in a subsequent pregnancy. 

In the domain of ART, my team and I were among the first to introduce cryo-embryo transfer in the natural cycle, following extensive research demonstrating that it yields pregnancy rates comparable to artificial cycles while reducing complications in pregnancy. 

I am actively involved in large-scale international trials and cohort studies, including the OMEGA cohort, which aims to generate comprehensive insights into the long-term health outcomes of ART for both women and children. We are currently working on research into the addition of Tamoxifen or Letrozole in women with breast cancer who wish to undergo oocyte cryopreservation.